Previous 10 |
The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more ...
MENLO PARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executiv...
Forty Seven ( FTSV ) made a solid bullish movement as predicted in our last analysis piece for this stock, as it broke above the bullish pennant to hit a high of just under $24 in December 2018. The price has since cooled off from that point, retreating to about $13 before resuming a climb...
MENLO PARK, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that company management will participate in a fireside chat a...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...